Rituximab: a review of dermatological applications.
Authors:
- Jason J EmerJEJason J Emer
- Wolinsky ClaireWCWolinsky Claire
- 1 May 2009
- journal article
- Vol. 2 (5) , 29-37
Abstract
The treatment of many dermatological disorders, such as autoimmune and immune-mediated diseases, consists of the use of systemic corticosteroids alone or in combination with other steroid-sparing immunosuppressants. Often, these treatment regimens are sufficient to control disease activity with relatively few side effects if monitored by a diligent physician. Some patients, however, may be refractory to treatment or develop intolerable side effects from therapy. For these patients, alternative treatment modalities with less toxicity and greater efficacy are required. Rituximab is a genetically engineered, chimeric monoclonal antibody directed against the B-cell lineage specific CD20 antigen. Originally developed for the treatment of B-cell non-Hodgkin"s lymphoma, rituximab has increasingly been used to treat a variety of autoimmune and immune-mediated disorders, such as rheumatoid arthritis, pemphigus diseases, systemic lupus erythematosus, dermatomyositis, and idiopathic thrombocytopenic purpura to name a few. Since very few randomized, controlled, clinical trials exist regarding the use of rituximab in the treatment of dermatological disorders, guidelines for the off-label use of this medication come from anecdotal case reports and cohort studies. Further clinical studies are needed to validate the safety and efficacy of rituximab therapy in dermatological disorders. Until then, we present a literature review of the emerging use of this B-cell depletion therapy. (J Clin Aesthetic Dermatol. 2009;2(5):29-37.).Keywords
This publication has 82 references indexed in Scilit:
- Off-label uses of rituximab in dermatologyDermatologic Therapy, 2007
- Rituximab in autoimmune bullous diseases: mixed responses and adverse effectsBritish Journal of Dermatology, 2007
- Intralesional and intravenous treatment of cutaneous B-cell lymphomas with the monoclonal anti-CD20 antibody rituximab: report and follow-up of eight casesBritish Journal of Dermatology, 2006
- Systemic eight-cycle anti-CD20 monoclonal antibody (rituximab) therapy in primary cutaneous B-cell lymphomas - an applicational observationBritish Journal of Dermatology, 2005
- Rituximab-mediated depletion of cynomolgus monkey B cells in vitro in different matrices: possible inhibitory effect of IgGInternational Immunopharmacology, 2004
- Skin involvement in dermatomyositisCurrent Opinion in Rheumatology, 2003
- Polymyositis and dermatomyositisThe Lancet, 2003
- Reduction of tumor burden and stabilization of disease by systemic therapy with anti‐CD20 antibody (rituximab) in patients with primary cutaneous B‐cell lymphomaCancer, 2000
- Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma.1994
- Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20.1994